

Seitaro Terakura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2967000/publications.pdf>

Version: 2024-02-01

97
papers

2,111
citations

279798

23
h-index

254184

43
g-index

100
all docs

100
docs citations

100
times ranked

2912
citing authors

#	ARTICLE	IF	CITATIONS
1	Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 Chimeric Antigen Receptor-Modified Effector CD8+ T Cells. <i>Journal of Immunology</i> , 2015, 194, 911-920.	0.8	228
2	Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. <i>Blood</i> , 2012, 119, 72-82.	1.4	186
3	A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. <i>Cancer Immunology Research</i> , 2016, 4, 658-668.	3.4	135
4	Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. <i>Blood</i> , 2017, 130, 1985-1994.	1.4	127
5	The activated conformation of integrin $\alpha 7$ is a novel multiple myeloma-specific target for CAR T cell therapy. <i>Nature Medicine</i> , 2017, 23, 1436-1443.	30.7	105
6	Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 330-338.	2.0	100
7	Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2004, 33, 1143-1150.	2.4	87
8	Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. <i>Bone Marrow Transplantation</i> , 2007, 39, 31-39.	2.4	66
9	Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. <i>Blood</i> , 2009, 114, 3113-3116.	1.4	63
10	Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell Doses. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 822-830.	2.0	55
11	Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. <i>Leukemia</i> , 2017, 31, 663-668.	7.2	54
12	GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. <i>Bone Marrow Transplantation</i> , 2017, 52, 1261-1267.	2.4	39
13	Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. <i>Bone Marrow Transplantation</i> , 2017, 52, 423-430.	2.4	37
14	A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. <i>British Journal of Haematology</i> , 2005, 129, 221-228.	2.5	35
15	A Single Minor Histocompatibility Antigen Encoded by UGT2B17 and Presented by Human Leukocyte Antigen-A*2902 and -B*4403. <i>Transplantation</i> , 2007, 83, 1242-1248.	1.0	35
16	Dexamethasone Palmitate Ameliorates Macrophages-Rich Graft-versus-Host Disease by Inhibiting Macrophage Functions. <i>PLoS ONE</i> , 2014, 9, e96252.	2.5	32
17	Unrelated cord blood transplantation vs related transplantation with HLA 1-antigen mismatch in the graft-versus-host direction. <i>Leukemia</i> , 2013, 27, 286-294.	7.2	31
18	Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2006, 37, 289-296.	2.4	30

#	ARTICLE	IF	CITATIONS
19	Oral ribavirin for severe adenovirus infection after allogeneic marrow transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 1107-1108.	2.4	27
20	Multiplex Real-time RT-PCR for Prospective Evaluation of WT1 and Fusion Gene Transcripts in Newly Diagnosed De Novo Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 1803-1808.	1.3	27
21	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. <i>Blood Advances</i> , 2019, 3, 105-115.	5.2	25
22	The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206. <i>Bone Marrow Transplantation</i> , 2007, 40, 165-174.	2.4	24
23	Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 363-369.	2.4	23
24	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. <i>Bone Marrow Transplantation</i> , 2021, 56, 2355-2366.	2.4	23
25	Long-Term Outcome after Bone Marrow Transplantation for Aplastic Anemia Using Cyclophosphamide and Total Lymphoid Irradiation as Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 43-49.	2.0	21
26	Cutaneous macrophage infiltration in acute GvHD. <i>Bone Marrow Transplantation</i> , 2015, 50, 1135-1137.	2.4	21
27	Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677T genotype. <i>International Journal of Hematology</i> , 2008, 87, 451-458.	1.6	20
28	Eosinophilia predicts better overall survival after acute graft-versus-host-disease. <i>Bone Marrow Transplantation</i> , 2010, 45, 371-377.	2.4	18
29	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2105-2114.	2.0	17
30	Composite CD79A/CD40 co-stimulatory endodomain enhances CD19CAR-T cell proliferation and survival. <i>Molecular Therapy</i> , 2021, 29, 2677-2690.	8.2	17
31	Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. <i>Bone Marrow Transplantation</i> , 2006, 37, 381-386.	2.4	16
32	Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality. <i>Clinical Infectious Diseases</i> , 2021, 73, e620-e628.	5.8	16
33	Stable Engraftment after a Conditioning Regimen with Fludarabine and Melphalan for Bone Marrow Transplantation from an Unrelated Donor. <i>International Journal of Hematology</i> , 2006, 83, 356-362.	1.6	15
34	Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 517-525.	2.0	15
35	Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells. <i>Medicine (United States)</i> , 2018, 97, e0449.	1.0	15
36	Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-versus-Host Disease Tissues. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 417-423.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Donor cell leukemia after allogeneic peripheral blood stem cell transplantation: a case report and literature review. <i>International Journal of Hematology</i> , 2008, 88, 111-115.	1.6	14
38	Introduction of Genetically Modified CD3 ζ Improves Proliferation and Persistence of Antigen-Specific CTLs. <i>Cancer Immunology Research</i> , 2018, 6, 733-744.	3.4	14
39	CTL Clones Isolated from an HLA-Cw-Mismatched Bone Marrow Transplant Recipient with Acute Graft-Versus-Host Disease. <i>Journal of Immunology</i> , 2009, 183, 5991-5998.	0.8	13
40	Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. <i>Stem Cells Translational Medicine</i> , 2021, 10, 542-553.	3.3	13
41	Phase I study of intrabone single unit cord blood transplantation for hematological malignancies. <i>Cancer Science</i> , 2017, 108, 1634-1639.	3.9	12
42	Successful Nonmyeloablative Bone Marrow Transplantation for Leukocyte Adhesion Deficiency Type I from an Unrelated Donor. <i>International Journal of Hematology</i> , 2007, 86, 91-95.	1.6	10
43	Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase II pharmacokinetics combined study. <i>Bone Marrow Transplantation</i> , 2009, 43, 611-617.	2.4	10
44	A prospective dose-finding trial using a modified continual reassessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors in patients with hematopoietic malignancies. <i>Annals of Oncology</i> , 2011, 22, 1865-1871.	1.2	10
45	Phase I study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. <i>Cancer Science</i> , 2012, 103, 1688-1694.	3.9	10
46	Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. <i>Annals of Hematology</i> , 2015, 94, 1139-1148.	1.8	10
47	Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. <i>Journal of Immunotherapy</i> , 2016, 39, 306-315.	2.4	10
48	Increased frequency of the angiotensin-converting enzyme gene D-allele is associated with noninfectious pulmonary dysfunction following allogeneic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2005, 36, 617-620.	2.4	9
49	Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection. <i>Bone Marrow Transplantation</i> , 2015, 50, 1187-1194.	2.4	9
50	Increase of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1164-1170.	2.4	9
51	Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. <i>International Journal of Hematology</i> , 2020, 111, 84-92.	1.6	9
52	Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2020, 55, 1399-1409.	2.4	9
53	Potential Role of a Mismatched HLA-Specific CTL Clone Developed Pre-Transplant in Graft Rejection following Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 397-402.	2.0	7
54	Identification of a novel HLA-A*24:02-restricted adenovirus serotype 11-specific CD8+ T-cell epitope for adoptive immunotherapy. <i>Molecular Immunology</i> , 2013, 56, 399-405.	2.2	7

#	ARTICLE	IF	CITATIONS
55	Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia. <i>PLoS ONE</i> , 2018, 13, e0204850.	2.5	7
56	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 840-850.	1.6	7
57	Artificial T Cell Adaptor Molecule-Transduced TCR-T Cells Demonstrated Improved Proliferation Only When Transduced in a Higher Intensity. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 613-622.	4.4	6
58	Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2231-2240.	2.4	6
59	High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-CG genotype. <i>PLoS ONE</i> , 2017, 12, e0185213.	2.5	6
60	Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 574-584.	5.2	6
61	Successful umbilical cord blood transplantation using a reduced-intensity preparative regimen without total body irradiation and tacrolimus plus methotrexate for prophylaxis of graft-versus-host disease in a patient with adult T-cell leukemia/lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 841-843.	1.3	5
62	Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults. <i>Bone Marrow Transplantation</i> , 2008, 41, 729-736.	2.4	5
63	Randomized controlled trial comparing ciprofloxacin and cefepime in febrile neutropenic patients with hematological malignancies. <i>International Journal of Infectious Diseases</i> , 2013, 17, e385-e390.	3.3	5
64	Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study. <i>Bone Marrow Transplantation</i> , 2017, 52, 612-614.	2.4	5
65	Virus-Associated Hemophagocytic Syndrome Caused by Pandemic Swine-Origin Influenza A (H1N1) in a Patient After Unrelated Bone Marrow Transplantation. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2011, 51, 63-65.	0.8	5
66	Serologically HLA-DR mismatched Unrelated Donors Might Provide a Valuable Alternative in Allogeneic Transplantation: Experience from a Single Japanese Institution. <i>International Journal of Hematology</i> , 2007, 85, 163-169.	1.6	4
67	Impact of the basal metabolic ratio in predicting early deaths after allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2009, 84, 608-611.	4.1	4
68	Simple and Efficient Generation of Virus-specific T Cells for Adoptive Therapy Using Anti-4-1BB Antibody. <i>Journal of Immunotherapy</i> , 2015, 38, 62-70.	2.4	4
69	Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Medicine (United States)</i> , 2017, 96, e9568.	1.0	4
70	Prospective Phase 2 Study of Umbilical Cord Blood Transplantation in Adult Acute Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 139-144.	2.0	4
71	Spacer Length Modification Facilitates Discrimination between Normal and Neoplastic Cells and Provides Clinically Relevant CD37 CAR T Cells. <i>Journal of Immunology</i> , 2021, 206, 2862-2874.	0.8	4
72	Randomised controlled trial of conditioning regimen for cord blood transplantation for adult myeloid malignancies comparing high-dose cytarabine/cyclophosphamide/total body irradiation with versus without G-CSF priming: G-CONCORD study protocol. <i>BMJ Open</i> , 2020, 10, e040467.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Chronic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation in Japan: Identification of Risk Factors and Prognostication.. Blood, 2005, 106, 1808-1808.	1.4	4
74	Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission. International Journal of Hematology, 2010, 91, 419-425.	1.6	3
75	Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 400-410.	2.4	3
76	A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. Annals of Hematology, 2021, 100, 743-752.	1.8	3
77	Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy. Transplantation and Cellular Therapy, 2021, 27, 342.e1-342.e10.	1.2	3
78	Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. Bone Marrow Transplantation, 2020, 55, 2098-2108.	2.4	3
79	Escape of leukemia blasts from HLA-specific CTL pressure in a recipient of HLA one locus-mismatched bone marrow transplantation. Cellular Immunology, 2012, 276, 75-82.	3.0	2
80	Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplantation, 2021, 56, 2990-2996.	2.4	2
81	Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 3059-3067.	2.4	2
82	Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. Bone Marrow Transplantation, 2022, 57, 243-251.	2.4	2
83	Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells. International Journal of Hematology, 2022, 115, 371.	1.6	2
84	Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 153.e1-153.e11.	1.2	2
85	Lymphoid blast crisis of chronic myelogenous leukemia occurring more than 11 years after receiving an allogeneic bone marrow transplant for chronic myelogenous leukemia in myeloid blast crisis at onset. Bone Marrow Transplantation, 2003, 31, 211-213.	2.4	1
86	Successful unrelated cord blood transplantation for adult acquired aplastic anemia using reduced intensity conditioning without ATG. Immunology Letters, 2014, 160, 99-101.	2.5	1
87	CAR-T cell therapy in combination with allogeneic stem cell transplantation. Journal of Hematopoietic Cell Transplantation, 2017, 6, 1-7.	0.1	1
88	Donor single nucleotide polymorphism in ACAT1 affects the incidence of graft-versus-host disease after bone marrow transplantation. International Journal of Hematology, 2020, 111, 112-119.	1.6	1
89	137: Potential Role of a Mismatched HLA-Specific CTL Clone Developed Pre-Transplant in Graft Rejection Following Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 52.	2.0	0
90	345: Decreased Risk of Acute GVHD Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with the 5,10-Methylenetetrahydrofolate Reductase 677TT Genotype. Biology of Blood and Marrow Transplantation, 2008, 14, 126-127.	2.0	0

#	ARTICLE	IF	CITATIONS
91	Characterization Of CTL Clones Isolated From Bone Marrow Transplant Recipient With HLA-Cw-Mismatched Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 118.	2.0	0
92	A CASE OF DELAYED ERYTHROPOIESIS AFTER BONE MARROW TRANSPLANTATION FROM AN ABO-COMPATIBLE SIBLING DONOR FOR ACQUIRED CHRONIC PURE RED CELL APLASIA. <i>Japanese Journal of Transfusion and Cell Therapy</i> , 2017, 63, 614-618.	0.2	0
93	High Incidence of Extensive Chronic Gvhd in Patients with the REG3A Rs7588571 Non-GG Genotype. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S192-S193.	2.0	0
94	Favorable Impact of Short Term Methotrexate on Early Immune Reaction and Non-Relapse Mortality in Umbilical Cord Blood Transplantation for Adult Patients.. <i>Blood</i> , 2006, 108, 5297-5297.	1.4	0
95	Steroid Therapy Increase Only Adenovirus Infection but Not Cytomegalovirus Infection in Dose Dependent Manner after Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5292-5292.	1.4	0
96	Donor Single Nucleotide Polymorphism in the CCR9 Gene Affects the Incidence of Acute Skin Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 1253-1253.	1.4	0
97	Generation and Signaling Function of CD19 Chimeric Antigen Receptor Modified CD8+ T Cells Derived From Virus-Specific Central Memory Cells for Adoptive Therapy After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2011, 118, 2978-2978.	1.4	0